Status:
ACTIVE_NOT_RECRUITING
The MISTRAL Study: Gut Microbiome Correlates of Serious AIDS and Non-AIDS Events
Lead Sponsor:
Rigshospitalet, Denmark
Collaborating Sponsors:
IrsiCaixa
Horizon 2020 - European Commission
Conditions:
HIV-1-infection
Inflammation
Eligibility:
All Genders
50+ years
Brief Summary
MISTRAL (Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications, antimicrobial drug resistance, and unresponsiveness to therapeutic HIV-1 vaccinati...
Detailed Description
Background and Rationale: The HIV/AIDS pandemic continues to be one of the major health challenges ever faced by mankind. Far from being resolved, HIV is soaring in Eastern Europe (60% increase in new...
Eligibility Criteria
Inclusion
- HIV-1 positive persons
- Age ≥50 years old
- Prospectively followed in a EuroSIDA site
Exclusion
- Creatine Clearance \<50
- Child-Pugh C end-stage liver disease
- Any ongoing severe life-threatening disease
- Experiencing any of the following events prior to inclusion: myocardial infarction, stroke, an invasive cardiovascular procedure, AIDS-defining infections (diagnosed with 5 years of MISTRAL enrolment), and prior AIDS cancer on non-AIDS cancers (excluding non-melanoma skin cancers)
Key Trial Info
Start Date :
September 28 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2025
Estimated Enrollment :
991 Patients enrolled
Trial Details
Trial ID
NCT05421286
Start Date
September 28 2022
End Date
December 1 2025
Last Update
April 11 2025
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Saint-Pierre Hospital
Brussels, Belgium, 1000
2
University Hospital of Infectious Diseases
Zagreb, Croatia
3
Faculty Hospital Bulovka
Prague, Czechia
4
Aarhus University Hospital
Aarhus, Denmark, 8200